Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...
Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...
4h
Gut Neurons Decoded: New Study Reveals How Food Allergies and Microbes Rewire Gut Neuronal Responses
The Food Allergy Science Initiative, Inc. (FASI)—In a groundbreaking study [1] published in Science, researchers from the ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...
Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...
The inaugural TCCI AI-Driven Science Symposium was held in San Francisco from Monday to Tuesday, bringing together three ...
Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...
Traditional breeding and genetic modification methods have struggled to keep pace with the rapid evolution of plant viruses. CRISPR/Cas systems, originally derived from bacterial immune responses, ...
The FDA has officially placed two of Intellia’s Phase III studies under clinical hold after the biotech reported earlier this ...
We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by rewriting it.
USA-based Intellia Therapeutics has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase ...
Discover Revvity, Inc.’s latest earnings, cloud growth, and $1B buyback. Click for my updated look at RVTY stock and why I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback